How endogenous processes and metabolism differ between RC structures

Question

What has interested me for a while — and what I don't see discussed here much yet — is how differently various RCs are broken down and processed in the body. Not just whether they bind to specific receptors, but what happens *after* that binding: which metabolites are formed, how quickly they are excreted, and exactly what role structure plays in that process.

Take, for example, the differences between a tryptamine like 4-HO-DMT and a phenethylamine like 2C-B. Both can interact with serotonin systems, but the way they are metabolized is very different—and that has implications for duration of effect, toxicity, and even storage stability. For people interested more in science than in street talk, those nuances often remain underexposed.

More specifically: within synthetic cannabinoids, you see that variants like JWH-018 and later generations such as 5F-MDMB-PINACA produce completely different metabolites, which partly explains why some generations react much more erratically in certain people.

You see the same thing with dissociatives: the way ketamine, for example, is broken down compared to something like 3-MeO-PCP is not just a matter of speed, but of which intermediate products are formed and how they, in turn, interact with enzymes.

I would like to hear from others:

What metabolic differences have you noticed in different RCs?

- Do you see patterns between certain substitutions and the way the body processes them?

- Do you have scientific literature or interesting sources that shed more light on this?

I think this kind of discussion helps to better understand the science behind RCs, instead of just focusing on “experiences” or effects.

Marcel · Accepted Answer

The effect of a substance depends not only on where it binds in the brain, but also on what your body does with it afterwards. As soon as a substance has done its job, your body tries to break it down and clear it away. How this happens varies greatly depending on the substance, and that explains why some substances work for a short time and are predictable, while others linger for a long time or have very different effects on people.

Tryptamines vs. phenethylamines

A substance like 4-HO-DMT (this is psilocin) closely resembles serotonin, and the body recognizes this substance quickly. As a result, the liver can relatively easily neutralize this substance and excrete it via the urine. This fits the picture that the effect is clear, but also fades away quite cleanly.

With a substance like 2C-B That works differently. It has a completely different profile and must first be converted in multiple steps before it can leave the body. That process takes more time and varies more from person to person. That explains why 2C-B often works longer and why people sometimes experience the after-effects differently than with tryptamines.

Why synthetic cannabinoids break down slowly

With older synthetic cannabinoids, such as JWH-018, you see that the body breaks them down step by step into forms that can then be properly excreted. This makes the effect and duration slightly more predictable, although they remain potent.

With newer variants, such as 5F-MDMB-PINACA, there is a kind of breakpoint in the structure. It breaks down rapidly in the body, but in a way that can vary significantly from person to person. This sometimes creates intermediate products that are still potent. That is a major reason why these newer substances are known to be unpredictable and sometimes dangerous, even at low doses.

Dissociatives and differences in “aftermath”

Ketamine is converted in the body into other substances that remain partially active. This explains why the effect sometimes seems to come in waves and why people still feel something after the main effect has worn off.

With substances like 3-MeO-PCP, much depends on an individual's liver enzymes. Some people break it down quickly, others much more slowly. As a result, the same dose can have a relatively short-lasting effect in one person and an extremely long-lasting effect in another, with more side effects.

Patterns that you often see

Generally speaking, substances that are easy for the body to “catch” are cleared more quickly. Substances that must first be converted often remain active longer and result in greater variation between individuals. Small chemical differences, such as an extra fluorine atom or a different side group, can therefore have major consequences for duration, intensity, and risks.

Why this is important

This shows that two substances that act on the same system on paper can feel and have very different effects in practice. Not because they are so different in the brain, but because the body processes them completely differently. By examining this, you better understand why some substances are relatively stable and others notorious for their unpredictability. That is precisely the layer beneath the “experiences” where real science begins.

Important sources

I use a lot of PubMed sources to consult studies. With NPS, the information is often limited, however, because the studies are mainly focused on the more well-known psychedelics such as psilocybin, LSD, ketamine, and MDMA. Still, you can find some information on PubMed, like this. research into 2CB.

Better · Answer

Good points, @marcel! I would like to add some details here to make the picture more complete:

CYP450 enzymes and genetic variation

You rightly point out that people react differently to substances like 3-MeO-PCP, but it is good to know that this is often genetically determined. Cytochrome P450 enzymes (especially CYP2D6 and CYP3A4) vary enormously between individuals due to polymorphisms. Some people are "poor metabolizers," others "ultra-rapid metabolizers." This explains why the same dose works for 6 hours in one person and 18+ hours in another. This is no coincidence, but genetics.

MAO and why some tryptamines work orally

A crucial point regarding tryptamines: monoamine oxidase (MAO-A) rapidly breaks down most tryptamines. Therefore, DMT does not work orally, whereas 4-HO-DMT does. The structural modifications (that hydroxyl group at position 4) confer partial MAO resistance to psilocin. This is essential to understanding why small structural differences make such a big difference in efficacy.

Phase I and Phase II metabolism

What you describe actually falls under two categories:

Phase I (oxidation, reduction, hydrolysis): often creates still active metabolites. This explains the "waves" with ketamine and the aftermath of some substances.
Phase II (conjugation): makes substances water-soluble for excretion, usually inactive end products

This distinction helps explain why some substances have a distinct "afterglow" while others stop abruptly.

Why fluorination is used so often

You mention the fluorine atom, but not why. Fluorine substitution is deliberately used in synthetic cannabinoids to achieve two things:

Higher lipophilicity (crosses the blood-brain barrier better)
Metabolic stability (harder to break down)

This makes substances more potent, but also more dangerous. This is because they remain in the body longer and accumulate more quickly with reuse.

First-pass metabolism

Also relevant: the route of administration makes a huge difference. Oral? Then almost everything passes through the liver first (first-pass), and a small to larger portion via the mucous membranes. Nasal, sublingual, or smoked? Then you largely bypass that first liver passage. That is why the same substance can feel completely different via different routes and also have different safety profiles.

Harm reduction consequences

The most important practical point: structural similarity does NOT always mean an identical safety profile. Two substances that both act on 5-HT2A receptors can have completely different metabolic pathways, with different risks, different durations, and different unpredictability. This is precisely why "this substance looks like X, so it must be safe" is such a dangerous assumption, since it can differ from substance to substance.

Sources

In addition to PubMed, it is also good to look at:

Drug Bank for pharmacological data
EMCDDA (European Monitoring Centre) reports on NPS metabolism
Forensic toxicology journals that are often the first to identify new metabolites